Implementing HLA-B*58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A qualitative study from doctors’ and patients’ perspective
Introduction Allopurinol, the first-line treatment for chronic gout, is a common causative drug for severe cutaneous adverse reactions (SCAR). HLA-B*58:01 allele was strongly associated with allopurinol-induced SCAR in Asian countries such as Taiwan, Japan, Thailand and Malaysia. HLA-B*58:01 screeni...
Saved in:
Main Authors: | Ng, Wei Leik, Hussein, Norita, Ng, Chirk Jenn, Qureshi, Nadeem, Lee, Yew Kong, Kwan, Zhenli, Kee, Boon Pin, Then, Sue-Mian, Abdul Malik, Tun Firzara, Zaidan, Fatimah Zahrah Mohd, Azmi, Siti Umi Fairuz |
---|---|
Format: | Article |
Published: |
Public Library of Science
2024
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/44932/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Implementing HLA-B*58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A qualitative study from doctors' and patients' perspective
by: Ng, Wei Leik, et al.
Published: (2024) -
Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population
by: Chong, Huey Yi, et al.
Published: (2017) -
Is family history still underutilised? exploring the views and experiences of primary care doctors in Malaysia
by: Hussein, Norita, et al.
Published: (2020) -
The relevance of HLA-B*5801 pharmacogenotyping in personalising allopurinol therapy / Norleen Mohamed Ali
by: Mohamed Ali, Norleen
Published: (2016) -
Incidence of allopurinol-induced severe cutaneous adverse drug reaction in Malaysia
by: Ng, Wei Leik, et al.
Published: (2022)